1st Group (ASX:1ST) - Managing Director & CEO, Klaus Bartosch
Managing Director & CEO, Klaus Bartosch
Sourced: Gold Coast Bulletin
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Australian digital health company 1st Group (1ST) has told investors its operations will be immune to COVID-19
  • The company’s staff are now working efficiently and effectively from home
  • It’s health service portal, MyHealth1st, will release new platform updates to help with the pandemic
  • Additionally, 1st Group’s online appointments have surged over 350 per cent in the last two weeks
  • On the market this afternoon, 1st Group is down 16.7 per cent and is selling shares for 2.5¢ apiece

Australian digital health company 1st Group (1ST) has told investors its operations will be immune to COVID-19.

The company’s staff are now all working efficiently and effectively from home, with all domestic and international travel suspended.

It’s health service portal, MyHealth1st, will soon release new platform updates. The updates will provide its customers with COVID-19 patient screening and educational resources.

Managing Director Klaus Bartosch says the outbreak us generating more awareness of its online platforms for health professionals.

Additionally, 1st Group’s online appointments have surged over 350 per cent in the last two weeks.

The company said that it has experienced no negative operational impacts from COVID-19.

“We are also releasing further system upgrades shortly which will assist our customers to more easily screen patients making appointments for COVID-19 risk factors,” Klaus said.

“In these challenging times, we remain dedicated to the over 11m patients and 11k locations which use our technology, giving them a high-quality experience to drive better health outcomes,” he added.

1st Group also reported its annual recurring revenue for the third quarter is already at $5.3 million, which is up 7 per cent on the second quarter.

On the market this afternoon, 1st Group is down 16.7 per cent and is selling shares for 2.5¢ apiece at 12:51 pm AEDT.

1ST by the numbers
More From The Market Online

Telix Pharma gears up to launch US IPO

Telix Pharmaceuticals has announced it's working with Morgan Stanley to list depository shares on the NASDAQ.

This stock provides Oz’s only HIV self-test kit – and it’s bullish on the budget

Atomo Diagnostics is the only company in Australia that provides TGA-approved HIV self-test kits. It says…

Recce Pharma heading closer to full efficacy data for flagship R327

Recce Pharma has announced the latest cohort of patients in the company's Phase I/II UTI trial…